|
WO2016008005A1
|
|
Galectin immunotherapy
|
|
WO2015058260A1
|
|
Dendritic cell assay for immunomodulatory molecules
|
|
CA2921774A1
|
|
Immunoreceptor modulation for treating cancer and viral infections
|
|
US2011165181A1
|
|
Relay vaccine
|
|
WO2009143578A1
|
|
Cancer drug target and methods of diagnosis and therapy
|
|
WO2009135257A1
|
|
Methods of diagnosis of inflammatory bowel disease
|
|
WO2009047488A1
|
|
Method of screening for anticancer agents
|
|
WO2007085057A1
|
|
A medical protocol
|
|
WO2007014415A1
|
|
Helminth antigen and immunotherapy
|
|
AU2006214792A1
|
|
Flavivirus replicon constructs for tumour therapy
|
|
WO2006086838A1
|
|
Flavivirus replicon constructs for tumour therapy
|
|
CA2597008A1
|
|
Immunogenic molecules
|
|
WO2006056027A1
|
|
Human cytomegalovirus immunotherapy
|
|
CN101084239A
|
|
Truncated LHRH formulations
|
|
WO2005090569A1
|
|
Cancer and testis vsm1 and vsm2 nucleic acids, proteins and uses thereof
|
|
US2007041937A1
|
|
G-csf derivative for inducing immunological tolerance
|
|
WO2005018665A1
|
|
Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium spp
|
|
US2005002956A1
|
|
Vaccine
|
|
WO2004041849A1
|
|
Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
|
|
CA2494192A1
|
|
Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
|
